CDTX Cidara Therapeutics Inc

Cidara Therapeutics Inc mainly develops anti-infective drugs in the United States. It attends to serious fungal infections through its drug candidates and proprietary immunotherapy technology platform, CloudbreakTM.

As of 04/09/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/15/2015
Outstanding shares:  48,043,143
Average volume:  924,949
Market cap:   $110,499,229
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    171757107
ISIN:        US1717571079
Sedol:      BWTVW67
Valuation   (See tab for details)
PE ratio:   -1.48
PB ratio:   9.62
PS ratio:   9.16
Return on equity:   -672.99%
Net income %:   -597.59%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy